Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2012

Open Access 01-12-2012 | Research article

Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients

Authors: Jose Hinz, Philipp Gehoff, Hanna Schotola, Morteza Tavakkoli Hosseini, Vassilios N Didilis, Ahmad Fawad Jebran, Anastasia Gehoff, Christoph H Wiese, Egbert Godehard Schulz, Friedrich Albert Schoendube, Aron Frederik Popov

Published in: Journal of Cardiothoracic Surgery | Issue 1/2012

Login to get access

Abstract

Background

Peri-operative statin therapy in cardiac surgery cases is reported to reduce the rate of mortality, stroke, postoperative atrial fibrillation, and systemic inflammation. Systemic inflammation could affect the hemodynamic parameters and stability. We set out to study the effect of statin therapy on perioperative hemodynamic parameters and its clinical outcome.

Methods

In a single center study from 2006 to 2007, peri-operative hemodynamic parameters of 478 patients, who underwent cardiac surgery with cardiopulmonary bypass, were measured. Patients were divided into those who received perioperative statin therapy (n = 276; statin group) and those who did not receive statin therapy (n = 202; no-statin group). The two groups were compared together using Kolmogorov-Smirnov-Test, Fisher’s-Exact-Test, and Student’s-T-test. A p value < 0.05 was considered as significant.

Results

There was no significant difference in the preoperative risk factors. Onset of postoperative atrial fibrillation was not affected by statin therapy. Extended hemodynamic measurements revealed no significant difference between the two groups, apart from Systemic Vascular Resistance Index (SVRI) . The no-statin group had a significantly higher SVRI (882 ± 206 vs. 1050 ± 501 dyn s/cm5/m2, p = 0.022). Inotropic support was the same in both groups and no significant difference in the mortality rate was noticed. Also, hemodynamic parameters were not affected by different types and doses of statins.

Conclusions

Perioperative statin therapy for patients undergoing on-pump coronary bypass grafting or valvular surgery, does not affect the hemodynamic parameters and its clinical outcome.
Literature
1.
go back to reference Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361 (9374): 2005-2016.CrossRefPubMed Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361 (9374): 2005-2016.CrossRefPubMed
2.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004, 44 (3): 720-732. 10.1016/j.jacc.2004.07.001.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004, 44 (3): 720-732. 10.1016/j.jacc.2004.07.001.CrossRefPubMed
3.
go back to reference Levine GN, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995, 332 (8): 512-521. 10.1056/NEJM199502233320807.CrossRefPubMed Levine GN, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995, 332 (8): 512-521. 10.1056/NEJM199502233320807.CrossRefPubMed
4.
go back to reference Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279 (20): 1615-1622. 10.1001/jama.279.20.1615.CrossRefPubMed Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279 (20): 1615-1622. 10.1001/jama.279.20.1615.CrossRefPubMed
5.
go back to reference Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335 (14): 1001-1009. 10.1056/NEJM199610033351401.CrossRefPubMed Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335 (14): 1001-1009. 10.1056/NEJM199610033351401.CrossRefPubMed
6.
go back to reference Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998, 339 (19): 1349-1357. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998, 339 (19): 1349-1357.
7.
go back to reference Liao JK: Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005, 96 (5A): 24F-33F.CrossRefPubMedPubMedCentral Liao JK: Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005, 96 (5A): 24F-33F.CrossRefPubMedPubMedCentral
8.
go back to reference Halcox JP, Deanfield JE: Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004, 109 (21 Suppl 1): II42-II48.PubMed Halcox JP, Deanfield JE: Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004, 109 (21 Suppl 1): II42-II48.PubMed
9.
go back to reference Ito MK, Talbert RL, Tsimikas S: Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006, 26 (7 Pt 2): 85S-97S. discussion 98S-101S; quiz 106S-108SCrossRefPubMed Ito MK, Talbert RL, Tsimikas S: Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006, 26 (7 Pt 2): 85S-97S. discussion 98S-101S; quiz 106S-108SCrossRefPubMed
10.
go back to reference Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T: Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008, 29 (12): 1548-1559. 10.1093/eurheartj/ehn198.CrossRefPubMed Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T: Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008, 29 (12): 1548-1559. 10.1093/eurheartj/ehn198.CrossRefPubMed
11.
go back to reference Butler J, Rocker GM, Westaby S: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993, 55 (2): 552-559. 10.1016/0003-4975(93)91048-R.CrossRefPubMed Butler J, Rocker GM, Westaby S: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993, 55 (2): 552-559. 10.1016/0003-4975(93)91048-R.CrossRefPubMed
12.
go back to reference Casey LC: Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg. 1993, 56 (5 Suppl): S92-S96.CrossRefPubMed Casey LC: Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Ann Thorac Surg. 1993, 56 (5 Suppl): S92-S96.CrossRefPubMed
13.
go back to reference Hsu LC: Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997, 11 (3): 376-382. 10.1016/S1053-0770(97)90108-7.CrossRefPubMed Hsu LC: Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997, 11 (3): 376-382. 10.1016/S1053-0770(97)90108-7.CrossRefPubMed
14.
go back to reference Hill GE: Cardiopulmonary bypass-induced inflammation: is it important?. J Cardiothorac Vasc Anesth. 1998, 12 (2 Suppl 1): 21-25.PubMed Hill GE: Cardiopulmonary bypass-induced inflammation: is it important?. J Cardiothorac Vasc Anesth. 1998, 12 (2 Suppl 1): 21-25.PubMed
15.
go back to reference Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420 (6911): 78-84. 10.1038/nature01158.CrossRefPubMed Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420 (6911): 78-84. 10.1038/nature01158.CrossRefPubMed
16.
go back to reference Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F, Carassiti M, Covino E: Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006, 34 (3): 660-667. 10.1097/01.CCM.0000201407.89977.EA.CrossRefPubMed Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F, Carassiti M, Covino E: Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006, 34 (3): 660-667. 10.1097/01.CCM.0000201407.89977.EA.CrossRefPubMed
17.
go back to reference Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Di Sciascio G, Covino E: Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg. 2007, 83 (4): 1374-1380. 10.1016/j.athoracsur.2006.10.065.CrossRefPubMed Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Di Sciascio G, Covino E: Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg. 2007, 83 (4): 1374-1380. 10.1016/j.athoracsur.2006.10.065.CrossRefPubMed
18.
go back to reference Thal AP, Wilson RF: Shock. Curr Probl Surg. 1965, 1-62. Thal AP, Wilson RF: Shock. Curr Probl Surg. 1965, 1-62.
19.
go back to reference Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F: Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999, 15 (6): 816-822. 10.1016/S1010-7940(99)00106-2. discussion 822–813CrossRefPubMed Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F: Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999, 15 (6): 816-822. 10.1016/S1010-7940(99)00106-2. discussion 822–813CrossRefPubMed
20.
go back to reference Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8 (4): R204-R212. 10.1186/cc2872.CrossRefPubMedPubMedCentral Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8 (4): R204-R212. 10.1186/cc2872.CrossRefPubMedPubMedCentral
21.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13 (10): 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13 (10): 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed
22.
go back to reference Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270 (24): 2957-2963. 10.1001/jama.1993.03510240069035.CrossRefPubMed Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270 (24): 2957-2963. 10.1001/jama.1993.03510240069035.CrossRefPubMed
23.
go back to reference Boeken U, Feindt P, Mohan E, Zimmermann N, Micek M, Kalweit G, Gams E: Post-perfusion syndrome and disturbed microcirculation after cardiac surgery: the role of angiotensin-converting-enzyme inhibitors. Thorac Cardiovasc Surg. 1999, 47 (6): 347-351. 10.1055/s-2007-1013172.CrossRefPubMed Boeken U, Feindt P, Mohan E, Zimmermann N, Micek M, Kalweit G, Gams E: Post-perfusion syndrome and disturbed microcirculation after cardiac surgery: the role of angiotensin-converting-enzyme inhibitors. Thorac Cardiovasc Surg. 1999, 47 (6): 347-351. 10.1055/s-2007-1013172.CrossRefPubMed
24.
go back to reference Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 145-153.CrossRefPubMed Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 145-153.CrossRefPubMed
25.
go back to reference Borger MA, Seeburger J, Walther T, Borger F, Rastan A, Doenst T, Mohr FW: Effect of preoperative statin therapy on patients undergoing isolated and combined valvular heart surgery. Ann Thorac Surg. 2010, 89 (3): 773-779. 10.1016/j.athoracsur.2009.12.001.CrossRefPubMed Borger MA, Seeburger J, Walther T, Borger F, Rastan A, Doenst T, Mohr FW: Effect of preoperative statin therapy on patients undergoing isolated and combined valvular heart surgery. Ann Thorac Surg. 2010, 89 (3): 773-779. 10.1016/j.athoracsur.2009.12.001.CrossRefPubMed
Metadata
Title
Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients
Authors
Jose Hinz
Philipp Gehoff
Hanna Schotola
Morteza Tavakkoli Hosseini
Vassilios N Didilis
Ahmad Fawad Jebran
Anastasia Gehoff
Christoph H Wiese
Egbert Godehard Schulz
Friedrich Albert Schoendube
Aron Frederik Popov
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2012
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/1749-8090-7-39

Other articles of this Issue 1/2012

Journal of Cardiothoracic Surgery 1/2012 Go to the issue